Study design and participants
DISEASE, RECURRENCE
The DATA study (NCT00301457) was an open-label, phase 3, randomized controlled trial in which postmenopausal women with HR+ BC received either 6 or 3 years of anastrozole (1 mg orally once a day) after completing 2 to 3 years of adjuvant treatment with tamoxifen without signs of disease recurrence (For the current analysis, all patients with a baseline BMI measurement were selected. Underweight patients (BMI: <18.5 kg/mThis study was approved by the medical ethics committee of the Radboud University Medical Centre (Nijmegen, the Netherlands). Written informed consent was obtained from all patients.